Shots:
- P-Ib/II (TUPELO) trial (enrolment ongoing) assessed REC-4881 (4 or 8mg, QD) in FAP, with P-II evaluating efficacy via upper & lower endoscopy at Wk. 0, 13 (on-treatment), & 25 (off-treatment) in pts (≥55yrs.) with APC mutations
- As of Mar 17, 2025, 4mg (n=6) showed a median 43% polyp burden decrease; 5/6 had reductions of 31% to 82%, while 1 had a 595% increase. 3 pts had >50% decrease at Wk. 13; 2 maintained >30% reduction at Wk. 25, while 1 didn’t undergo endoscopic evaluation at Wk. 25
- At Wk. 13, 3 pts had a ≥1-pt Spigelman stage reduction; 1 had no change, 1 progressed from Stage II to IV, & 1 had no baseline stage but was Stage II at Wk. 13; further efficacy & safety analyses expected in H2’25
Ref: Recursion | Image: Recursion
Related News:- AstraZeneca Reports P-III (LOGOS & KALOS) Trial Findings of Breztri Aerosphere for Uncontrolled Asthma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click Here for the Full Press Release
